HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Praxis Precision Medicine (NASDAQ:PRAX), but has lowered the price target from $15 to $7.
August 10, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Praxis Precision Medicine's price target has been lowered from $15 to $7 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a short-term negative impact on Praxis Precision Medicine's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100